# CKD-330 Phase 3 Trial in Amlodipine Non-responder

Study · id `cardio:ct-nct02586311` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02586311](<https://clinicaltrials.gov/study/NCT02586311>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02586311

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT02586311. Randomized; double masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT02586311, source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT02586311, source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)
- Primary completion: 2016-08 (actual) (ClinicalTrials.gov record NCT02586311, source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02586311, source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02586311, source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02586311-2016-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: CKD-330 Phase 3 Trial in Amlodipine Non-responder
- Condition: Hypertension
- Intervention (Drug): CKD-330 16/5mg
- Intervention (Drug): Amlodipine 5mg Placebo
- Intervention (Drug): CKD-330 16/5mg Placebo
- Intervention (Drug): Amlodipine 5mg
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: efabd18a3d620aa154e161acecc2475ee862472782955010d705a1435255edc3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
